- Author: Dianna Quan, MD; Chief Editor: Romesh Khardori, MD, PhD, FACP more...
Diabetic neuropathy is the most common complication of diabetes mellitus (DM), affecting as many as 50% of patients with type 1 and type 2 DM. Diabetic peripheral neuropathy involves the presence of symptoms or signs of peripheral nerve dysfunction in people with diabetes after other possible causes have been excluded.
Signs and symptoms
In type 1 DM, distal polyneuropathy typically becomes symptomatic after many years of chronic prolonged hyperglycemia, whereas in type 2, it may be apparent after only a few years of known poor glycemic control or even at diagnosis. Symptoms include the following:
Sensory – Negative or positive, diffuse or focal; usually insidious in onset and showing a stocking-and-glove distribution in the distal extremities
Motor – Distal, proximal, or more focal weakness, sometimes occurring along with sensory neuropathy (sensorimotor neuropathy)
Autonomic – Neuropathy that may involve the cardiovascular, gastrointestinal, and genitourinary systems and the sweat glands
Physical examination should include the following assessments:
Peripheral neuropathy testing – Gross light touch and pinprick sensation; vibratory sense; deep tendon reflexes; strength testing and muscle atrophy; dorsal pedal and posterior tibial pulses; skin assessment; Tinel testing; cranial nerve testing
Autonomic neuropathy testing – Objective evaluation of cardiovagal, adrenergic, and sudomotor function in a specialized autonomic laboratory; may be preceded by bedside screening to assess supine and upright blood pressure and heart rate, with measurement of sinus arrhythmia ratio
Two classification systems for diabetic neuropathy are the Thomas system and the symmetrical-versus-asymmetrical system. The Thomas system (modified) is as follows:
Generalized symmetrical polyneuropathies
Focal and multifocal neuropathies
Superimposed chronic inflammatory demyelinating polyneuropathy
Distal symmetrical sensorimotor polyneuropathy is commonly defined according to the following 3 key criteria:
The patient must have diabetes mellitus consistent with a widely accepted definition
Severity of polyneuropathy should be commensurate with duration and severity of diabetes
Other causes of sensorimotor polyneuropathy must be excluded
Pure autonomic diabetic neuropathy is rare.
Asymmetrical neuropathies include the following:
Median neuropathy of the wrist (carpal tunnel syndrome)
Other single or multiple limb mononeuropathies
Lumbosacral radiculoplexus neuropathy
Cervical radiculoplexus neuropathy
Diabetic polyneuropathy is commonly staged as follows:
NO - No neuropathy
N1a - Signs but no symptoms of neuropathy
N2a - Symptomatic mild diabetic polyneuropathy; sensory, motor, or autonomic symptoms; patient is able to heel-walk
N2b - Severe symptomatic diabetic polyneuropathy; patient is unable to heel-walk)
N3 - Disabling diabetic polyneuropathy
See Clinical Presentation for more detail.
Laboratory tests that may be helpful include the following:
Fasting plasma glucose
Complete blood count
Complete metabolic panel (electrolytes and liver function panel)
Vitamin B-12 and folate levels
Thyroid function tests
Erythrocyte sedimentation rate
Serum protein electrophoresis with immunofixation electrophoresis
Anti-SSA and SSB antibodies
Rapid plasma reagin
Hematology screen (for anemia)
Sequential multiple analysis-7 (renal function and electrolyte imbalances)/complete metabolic panel (CMP)
Other diagnostic modalities that may be considered are as follows:
Electromyography and nerve conduction velocity testing
Magnetic resonance imaging
Computed tomography (including single-photon emission computed tomography)
Nerve and skin biopsy (now rarely recommended for clinical purposes)
See Workup for more detail.
Key components of the management of diabetic neuropathy include the following:
Foot care, including regular follow-up, patient education, and referral as appropriate
Tight, stable glycemic control (most important for slowing progression of neuropathy)
Pain management (eg, with pregabalin, gabapentin, sodium valproate, dextromethorphan, morphine sulfate, tramadol, oxycodone, duloxetine, topical capsaicin, transdermal lidocaine)
Treatment of diabetic gastroparesis (eg, with erythromycin, cisapride [not available in the United States], metoclopramide, polyethylene glycol 3350, tegaserod [currently available only on an emergency basis])
Experimental therapies include aldose reductase inhibitors, alpha-lipoic acid, actovegin, and spinal cord stimulators.
Treatment of autonomic dysfunction must address the following:
Surgical treatment may be considered as follows:
Aggressive debridement or amputation for recalcitrant foot necrosis or infection
Jejunostomy for intractable gastroparesis
Implantation of a penile prosthesis for ongoing impotence
Bracing, special boots, or, in some cases, surgery for Charcot foot
Pancreatic transplantation for diabetes with end-stage renal disease
Neuropathies are characterized by a progressive loss of nerve fiber function. A widely accepted definition of diabetic peripheral neuropathy is "the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after exclusion of other causes."[1, 2]
Neuropathies are the most common complication of diabetes mellitus (DM), affecting up to 50% of patients with type 1 and type 2 DM. In type 1 diabetes mellitus, distal polyneuropathy typically becomes symptomatic after many years of chronic prolonged hyperglycemia. Conversely, patients with type 2 diabetes mellitus may present with distal polyneuropathy after only a few years of known poor glycemic control; sometimes, these patients already have neuropathy at the time of diagnosis. (See Clinical Presentation.)
Neuropathies severely decrease patients' quality of life (QOL). Furthermore, while the primary symptoms of neuropathy can be highly unpleasant, the secondary complications (eg, falls, foot ulcers, cardiac arrhythmias, and ileus) are even more serious and can lead to fractures, amputations, and even death in patients with DM.
Since diabetic neuropathy can manifest with a wide variety of sensory, motor, and autonomic symptoms, a structured list of symptoms can be used to help screen all diabetic patients for possible neuropathy (see History). Physical examination of patients with suspected distal sensory motor or focal (ie, entrapment or noncompressive) neuropathies should include assessments for both peripheral and autonomic neuropathy (see Physical Examination).
Multiple consensus panels recommend the inclusion of electrophysiologic testing in the evaluation of diabetic neuropathy. An appropriate array of electrodiagnostic tests includes both nerve conduction testing and needle EMG of the most distal muscles usually affected. (See Workup.)
Management of diabetic neuropathy should begin at the initial diagnosis of diabetes. The primary care physician needs to be alert for the development of neuropathy—or even its presence at the time of initial diabetes diagnosis—because failure to diagnose diabetic polyneuropathy can lead to serious consequences, including disability and amputation. In addition, the primary care physician is responsible for educating patients about the acute and chronic complications of diabetes (see Patient Education). Patients with diabetic peripheral neuropathy require more frequent follow-up, with particular attention to foot inspection to reinforce the need for regular self-care. (See Treatment Strategies and Management.)
Management of diabetic neuropathy includes 2 approaches: therapies for symptomatic relief and those that may slow the progression of neuropathy. Of all treatments, tight and stable glycemic control is probably the most important for slowing the progression of neuropathy. Many medications are available for the treatment of diabetic neuropathic pain, although most of them are not specifically approved by the United States Food and Drug Administration for this use. Nonpharmacologic treatment includes rehabilitation, which may comprise physical, occupational, speech, and recreational therapy. (See Medication.)
A review of the anatomy of the peripheral nervous system can facilitate understanding of the classification of diabetic peripheral neuropathy. Peripheral neurons can be categorized broadly as motor, sensory, or autonomic.
Motor neurons originate in the central nervous system (CNS) and extend to the anterior horn of the spinal cord. From the anterior horn, they exit the spinal cord (via ventral roots) and combine with other fibers in the brachial or lumbar plexuses and innervate their target organs through peripheral nerves.
Sensory neurons originate at the dorsal root ganglia (which lie outside the spinal cord) and follow a similar course with motor neurons. Sensory neurons are subdivided into categories according to the sensory modality they convey (see the Table below).
Autonomic neurons consist of sympathetic and parasympathetic types. In the periphery, preganglionic fibers leave the CNS and synapse on postganglionic neurons in the sympathetic chain or in sympathetic ganglia.
The smaller fibers are affected first in DM. With continued exposure to hyperglycemia, the larger fibers become affected. Fibers of different size mediate different types of sensation, as shown in the table below.
Table. Subdivisions of Sensory Neurons (Open Table in a new window)
|A-alpha (I)||13-20 micrometers||Limb proprioception||Yes|
|A-beta (II)||6-12 micrometers||Limb proprioception, vibration, pressure||Yes|
|A-delta (III)||1-5 micrometers||Mechanical sharp pain||Yes|
|C (IV)||0.2-1.5 micrometers||Thermal pain, mechanical burning pain||No|
The factors leading to the development of diabetic neuropathy are not understood completely, and multiple hypotheses have been advanced.[3, 4, 5, 6, 7, 8, 9, 10, 11, 12] It is generally accepted to be a multifactorial process. Development of symptoms depends on many factors, such as total hyperglycemic exposure and other risk factors such as elevated lipids, blood pressure, smoking, increased height, and high exposure to other potentially neurotoxic agents such as ethanol. Genetic factors may also play a role. Important contributing biochemical mechanisms in the development of the more common symmetrical forms of diabetic polyneuropathy likely include the polyol pathway, advanced glycation end products, and oxidative stress.
For more information, see Type 2 Diabetes and TCF7L2.
Hyperglycemia causes increased levels of intracellular glucose in nerves, leading to saturation of the normal glycolytic pathway. Extra glucose is shunted into the polyol pathway and converted to sorbitol and fructose by the enzymes aldose reductase and sorbitol dehydrogenase. Accumulation of sorbitol and fructose lead to reduced nerve myoinositol, decreased membrane Na+/K+ -ATPase activity, impaired axonal transport, and structural breakdown of nerves, causing abnormal action potential propagation. This is the rationale for the use of aldose reductase inhibitors to improve nerve conduction.
Advanced glycation end products
The nonenzymatic reaction of excess glucose with proteins, nucleotides, and lipids results in advanced glycation end products (AGEs) that may have a role in disrupting neuronal integrity and repair mechanisms through interference with nerve cell metabolism and axonal transport.
The increased production of free radicals in diabetes may be detrimental via several mechanisms that are not fully understood. These include direct damage to blood vessels leading to nerve ischemia and facilitation of AGE reactions. Despite the incomplete understanding of these processes, use of the antioxidant alpha-lipoic acid may hold promise for improving neuropathic symptoms.[17, 18, 19]
Related contributing factors
Problems that are a consequence of or co-contributors to these disturbed biochemical processes include altered gene expression with altered cellular phenotypes, changes in cell physiology relating to endoskeletal structure or cellular transport, reduction in neurotrophins, and nerve ischemia. Clinical trials of the best-studied neurotrophin, human recombinant nerve growth factor, were disappointing. With future refinements, however, pharmacologic intervention targeting one or more of these mechanisms may prove successful.
In the case of focal or asymmetrical diabetic neuropathy syndromes, vascular injury or autoimmunity may play more important roles.
Risk factors that are associated with more severe symptoms include the following :
Poor glycemic control
Long duration of DM
Heavy alcohol intake
Development of symptoms depends on many factors, such as total hyperglycemic exposure and other risk factors such as elevated lipids, blood pressure, smoking, increased height, and high exposure to other potentially neurotoxic agents such as ethanol. Genetic factors may also play a role.
Peripheral neuropathies have been described in patients with primary DM (types 1 and 2) and in those with secondary diabetes of diverse causes, suggesting a common etiologic mechanism based on chronic hyperglycemia. The contribution of hyperglycemia has received strong support from the Diabetes Control and Complications Trial (DCCT).
An association between impaired glucose tolerance and peripheral neuropathy has been construed as further evidence of a dose-dependent effect of hyperglycemia on nerves, although this relationship remains an area of some controversy for type 2 diabetes and prediabetes.[24, 25, 26, 27]
A study by Altaf et al indicated that obstructive sleep apnea (OSA) is linked to small-fiber neuropathy in type 2 diabetes, with poly–adenosine diphosphate ribose polymerase activation being a possible mechanism behind OSA’s association with diabetic peripheral neuropathy and endothelial dysfunction.
United States statistics
A large American study estimated that 47% of patients with diabetes have some peripheral neuropathy. Neuropathy is estimated to be present in 7.5% of patients at the time of diabetes diagnosis. More than half of cases are distal symmetric polyneuropathy. Focal syndromes such as carpal tunnel syndrome (14-30%),[30, 31, 32] radiculopathies/plexopathies, and cranial neuropathies account for the rest. Solid prevalence data for the latter 2 less-common syndromes is lacking.
The wide variability in symmetric diabetic polyneuropathy prevalence data is due to lack of consistent criteria for diagnosis, variable methods of selecting patients for study, and differing assessment techniques. In addition, because many patients with diabetic polyneuropathy are initially asymptomatic, detection is extremely dependent on careful neurologic examination by the primary care clinician. The use of additional diagnostic techniques, such as autonomic or quantitative sensory testing, might result in a higher recorded prevalence.[33, 34]
In a cohort of 4400 Belgian patients, Pirart et al found that 7.5% of patients already had neuropathy when diagnosed with diabetes. After 25 years, the number with neuropathy rose to 45%. In the United Kingdom, the prevalence of diabetic neuropathy among the hospital clinic population was noted to be around 29%.
Diabetic neuropathy in racial minorities
No definite racial predilection has been demonstrated for diabetic neuropathy. However, members of minority groups (eg, Hispanics, African Americans) have more secondary complications from diabetic neuropathy, such as lower-extremity amputations, than whites. They also have more hospitalizations for neuropathic complications.
Sex differences in diabetic neuropathy
DM affects men and women with equal frequency. However, male patients with type 2 diabetes may develop diabetic polyneuropathy earlier than female patients, and neuropathic pain causes more morbidity in females than in males.
Diabetic neuropathy and advancing age
Diabetic neuropathy can occur at any age but is more common with increasing age and severity and duration of diabetes.
Patients with untreated or inadequately treated diabetes have higher morbidity and complication rates related to neuropathy than patients with tightly controlled diabetes. Repetitive trauma to affected areas may cause skin breakdown, progressive ulceration, and infection. Amputations and death may result.
Treating diabetic neuropathy is a difficult task for the physician and patient. Most of the medicines mentioned in the Medication section do not lead to complete symptom relief. Clinical trials are under way to help find new ways to treat symptoms and delay disease progression.
Mortality is higher in people with cardiovascular autonomic neuropathy (CAN). The overall mortality rate over periods up to 10 years was 27% in patients with DM and CAN detected, compared with a 5% mortality rate in those without evidence of CAN. Morbidity results from foot ulceration and lower-extremity amputation. These 2 complications are the most common causes of hospitalization among people with DM in Western countries. Severe pain, dizziness, diarrhea, and impotence are common symptoms that decrease the QOL of a patient with DM. In patients with diabetic peripheral neuropathy, the prognosis is good, but the patient's QOL is reduced.
For more information, go to Diabetic Foot.
for more information, go to Diabetic Foot Infections.
Controlling diet and nutrition are paramount to improving the secondary complications of diabetes, including neuropathy. Patients with diabetic neuropathy should work with nutritionists or their primary care physicians to develop a realistic diet for lowering blood glucose and minimizing large fluctuations in blood glucose.
Patients with diabetic neuropathy should be encouraged to remain as active as possible. However, those with significant sensory loss or autonomic dysfunction should be cautioned about exercising in extreme weather conditions, which may result in injury. For example, patients with extremity numbness may not be aware of frostbite injuries during prolonged cold exposure, or those with abnormal sweating may become easily overheated in hot conditions. In most cases, consultation with the patient's regular physician is reasonable before the initiation of a regular exercise program.
Patients with diabetic neuropathy need to be educated on all aspects of their condition, and they need to know that it is very much affected by poor glycemic control. Prevention of diabetic neuropathy is potentially best achieved by having near-euglycemic control from the onset of DM. Even in patients with symptoms of diabetic neuropathy, controlling blood glucose to euglycemic levels reduces pain significantly. When a person has poor control and becomes euglycemic quickly, pain may be exacerbated (possibly due to an insulin effect), but this pain disappears in a few days. The bottom line for patients is that medications are imperfect. Many result in no pain relief for certain patients. However, glucose control is something that the patient can achieve that may reduce pain.
The importance of protection and care of insensitive feet cannot be overemphasized. Patients should be instructed to trim their toenails with great care and to be fastidious about foot hygiene. Any fungal or bacterial infection mandates prompt medical attention. The need for well-fitting shoes should be stressed.
Diabetic polyneuropathy is often associated with diabetic retinopathy and nephropathy. Patients with neuropathy should be counseled to seek appropriate eye care and discuss renal care and follow-up with their primary care physicians or endocrinologists.
Patient education should begin in the primary care office. The following outline reviews some common questions and answers that can serve as a springboard for discussion.
What is diabetic neuropathy?
Diabetic neuropathy is nerve damage caused by diabetes. In the United States, diabetes is one of the most common causes of nerve damage, also known as peripheral neuropathy. Diabetic neuropathy can affect nerves that supply feeling and movement in the arms and legs. It can also affect the nerves that regulate unconscious vital functions such as heart rate and digestion.
How does diabetic neuropathy occur?
Doctors have been studying this problem for many years, but they do not yet understand exactly how diabetes damages nerves. However, they have observed that good control of blood sugar levels helps prevent diabetic neuropathy and slows its progression, especially in patients with type 1 diabetes.
What are the symptoms?
Symptoms of diabetic neuropathy may include the following:
Numbness or loss of feeling (usually in the feet and legs first, then the hands)
Low blood pressure and dizziness when rising quickly from sitting or lying down
Rapid or irregular heartbeats
Trouble having an erection
Nausea or vomiting
Constipation or diarrhea
Pain from diabetic neuropathy may range from minor discomfort or tingling in toes to severe pain. Pain may be sharp or lightning-like, deep and aching, or burning. Extreme sensitivity to the slightest touch can also occur (allodynia).
A study by D’Amato et al indicated that among diabetes-related complications and comorbidities, painful diabetic polyneuropathy is the greatest determinant of depression in patients with diabetes. The study involved 181 patients, including 25 with painful diabetic polyneuropathy and 46 with the painless form of the condition.
How can I help prevent diabetic neuropathy?
The following steps may help to prevent or slow the worsening of diabetic neuropathy :
Control diabetes; try to keep blood sugar at a normal level
Maintain normal blood pressure
Exercise regularly, according to the healthcare provider's recommendation
Limit the amount of alcohol intake because excessive alcohol also can cause neuropathy or make it worse
Eat a healthy diet and avoid elevated levels of triglycerides in the blood
Maintain a healthy weight
Keep follow-up appointments with the healthcare provider
How is diabetic neuropathy treated?
No treatment is currently available to reverse neuropathy. The best approach is to control the diabetes and other risk factors.
Muscle weakness is treated with support, such as braces. Physical therapy and regular exercise may help patients maintain the muscle strength they have.
Pain medications may help make pain more tolerable. Medications can be used to treat nausea, vomiting, and diarrhea.
Men who have trouble having erections because of neuropathy should talk to their healthcare providers. Medications can help a man achieve and maintain an erection, or prosthetic devices can be put in the penis.
Preventing injuries such as burns, cuts, or broken bones is especially important, because patients with neuropathy have more complications from simple injuries and may not heal as quickly as healthy individuals.
How can I take care of myself?
Diabetes patients can take the following self-care measures:
Work with primary care physicians and endocrinologists to control glucose levels
Examine the skin of feet and lower legs regularly to look for injuries
See a healthcare provider promptly for calluses, sores on the skin, or other potential problems so they can be treated properly.
Wear good-fitting, comfortable shoes that protect the feet
How long will the problem last?
Once a person has neuropathy, the symptoms will persist indefinitely, but most people with diabetic neuropathy are able to lead active, fulfilling lives. Keeping blood sugar under good control may stop neuropathy from worsening.
For excellent patient education resources, visit eMedicineHealth's Diabetes Center and Men's Health Center. Also, see eMedicineHealth's patient education articles, Diabetes Mellitus and Diabetic Foot Care.
Boulton AJ, Malik RA. Diabetic neuropathy. Med Clin North Am. 1998 Jul. 82(4):909-29. [Medline].
Bromberg MB. Peripheral neurotoxic disorders. Neurol Clin. 2000 Aug. 18(3):681-94. [Medline].
Goetz CG, Pappert EJ. Textbook of Clinical Neurology. Philadelphia: WB Saunders Co; 1999.
Pourmand R. Diabetic neuropathy. Neurol Clin. 1997 Aug. 15(3):569-76. [Medline].
Sugimoto K, Murakawa Y, Sima AA. Diabetic neuropathy--a continuing enigma. Diabetes Metab Res Rev. 2000 Nov-Dec. 16(6):408-33. [Medline].
Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia. 2000 Aug. 43(8):957-73. [Medline].
Wilson JD. Williams Textbook of Endocrinology. 9th ed. Philadelphia: WB Saunders Co; 1998.
Zochodne DW. Diabetic polyneuropathy: an update. Curr Opin Neurol. 2008 Oct. 21(5):527-33. [Medline].
Calcutt NA, Dunn JS. Pain: Nociceptive and Neuropathic Mechanisms. Anesthesiology Clinics of North America.; 1997.
Malik RA. Pathology and pathogenesis of diabetic neuropathy. Diabetes Reviews. 1999. 7:253-60.
Shigeta H, Yamaguchi M, Nakano K, Obayashi H, Takemura R, Fukui M. Serum autoantibodies against sulfatide and phospholipid in NIDDM patients with diabetic neuropathy. Diabetes Care. 1997 Dec. 20(12):1896-9. [Medline].
Tavakkoly-Bazzaz J, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, Larijani B. VEGF gene polymorphism association with diabetic neuropathy. Mol Biol Rep. 2010 Mar 30. [Medline].
Carrington AL, Litchfield JE. The aldose reductase pathway and nonenzymatic glycation in the pathogenesis of diabetic neuropathy: a critical review for the end of the 20th century. Diabetes Reviews. 1999. 7:275-99.
Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology. 1999 Aug 11. 53(3):580-91. [Medline].
Ryle C, Donaghy M. Non-enzymatic glycation of peripheral nerve proteins in human diabetics. J Neurol Sci. 1995 Mar. 129(1):62-8. [Medline].
Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006 Nov. 29(11):2365-70. [Medline].
Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. 2008 Dec. 9(4):301-14. [Medline].
Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes. 1999. 107(7):421-30. [Medline].
Apfel SC, Kessler JA, Adornato BT, et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology. 1998 Sep. 51(3):695-702. [Medline].
Krendel DA, Zacharias A, Younger DS. Autoimmune diabetic neuropathy. Neurol Clin. 1997 Nov. 15(4):959-71. [Medline].
Dorsey RR, Eberhardt MS, Gregg EW, Geiss LS. Control of risk factors among people with diagnosed diabetes, by lower extremity disease status. Prev Chronic Dis. 2009 Oct. 6(4):A114. [Medline]. [Full Text].
Diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993 Sep 30. 329(14):977-86. [Medline].
Harati Y. Diabetes and the nervous system. Endocrinol Metab Clin North Am. 1996 Jun. 25(2):325-59. [Medline].
Rutkove SB. A 52-year-old woman with disabling peripheral neuropathy: review of diabetic polyneuropathy. JAMA. 2009 Oct 7. 302(13):1451-8. [Medline].
Finucane TE. Diabetic polyneuropathy and glucose control. JAMA. 2010 Feb 3. 303(5):420; author reply 420-1. [Medline].
Altaf QA, Ali A, Piya MK, Raymond NT, Tahrani AA. The relationship between obstructive sleep apnea and intra-epidermal nerve fiber density, PARP activation and foot ulceration in patients with type 2 diabetes. J Diabetes Complications. 2016 Jun 2. [Medline].
Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993 Apr. 43(4):817-24. [Medline].
Perkins BA, Olaleye D, Bril V. Carpal tunnel syndrome in patients with diabetic polyneuropathy. Diabetes Care. 2002 Mar. 25(3):565-9. [Medline].
Shaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Reviews. 1999. 7:245-52.
Singh R, Gamble G, Cundy T. Lifetime risk of symptomatic carpal tunnel syndrome in Type 1 diabetes. Diabet Med. 2005 May. 22(5):625-30. [Medline].
Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000 Feb. 47(2):123-8. [Medline].
Dyck PJ, O'Brien PC. Quantitative sensation testing in epidemiological and therapeutic studies of peripheral neuropathy. Muscle Nerve. 1999 Jun. 22(6):659-62. [Medline].
Pirart J. Diabetes mellitus and its degenerative complication: a prospective study of 4,400 patient observed between 1947 and 1973. Diabetes Care. 1978. 1:168-188.
Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993 Feb. 36(2):150-4. [Medline].
Aaberg ML, Burch DM, Hud ZR, Zacharias MP. Gender differences in the onset of diabetic neuropathy. J Diabetes Complications. 2008 Mar-Apr. 22(2):83-7. [Medline].
D'Amato C, Morganti R, Greco C, et al. Diabetic peripheral neuropathic pain is a stronger predictor of depression than other diabetic complications and comorbidities. Diab Vasc Dis Res. 2016 Jun 22. [Medline].
Tesfaye S, Watt J, Benbow SJ, Pang KA, Miles J, MacFarlane IA. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet. 1996 Dec 21-28. 348(9043):1698-701. [Medline].
Johnson DA, Vinik AI. Gastrointestinal Disturbances. Therapy for Diabetes Mellitus. American Diabetes Association; 1998.
Ziegler D. Cardiovascular autonomic neuropathy: clinical manifestations and measurement. Diabetes Reviews. 1999. 7:342-57.
Meijer JW, van Sonderen E, Blaauwwiekel EE, et al. Diabetic neuropathy examination: a hierarchical scoring system to diagnose distal polyneuropathy in diabetes. Diabetes Care. 2000 Jun. 23(6):750-3. [Medline].
Hokkam EN. Assessment of risk factors in diabetic foot ulceration and their impact on the outcome of the disease. Prim Care Diabetes. 2009 Nov. 3(4):219-24. [Medline].
Coppini DV, Wellmer A, Weng C, Young PJ, Anand P, Sönksen PH. The natural history of diabetic peripheral neuropathy determined by a 12 year prospective study using vibration perception thresholds. J Clin Neurosci. 2001 Nov. 8(6):520-4. [Medline].
Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001 Feb. 24(2):250-6. [Medline].
Dyck PJ, Turner DW, Davies JL, O'Brien PC, Dyck PJ, Rask CA. Electronic case-report forms of symptoms and impairments of peripheral neuropathy. Can J Neurol Sci. 2002 Aug. 29(3):258-66. [Medline].
Biaggioni I. Postural hypotension. Therapy for Diabetes Mellitus. American Diabetes Association; 1998. 423-30.
Ayad H. Diabetic neuropathy: classification, clinical manifestations, diagnosis and management. Baba S et al, eds. Diabetes Mellitus in Asia. Amsterdam: Excerpta Medica; 1977. 222-4.
Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes. 1997 Sep. 46 Suppl 2:S54-7. [Medline].
All About Diabetes. Date Accessed: October 30, 2008. American Diabetes Association. [Full Text].
Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: A report of the World Health Organization and International Diabetes Federation. Geneva, Switzerland: WHO Press; 2006.
Abbott CA, Vileikyte L, Williamson S, et al. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care. 1998 Jul. 21(7):1071-5. [Medline].
Llewelyn JG, Tomlinson DR, Thomas PK. Dyck PJ and Thomas PK. Diabetic Neuropathies in Peripheral Neuropathy. Philadelphia: Elsevier Saunders; 2005. 1951-91.
Lozeron P, Nahum L, Lacroix C, Ropert A, Guglielmi JM, Said G. Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients. J Neurol. 2002 May. 249(5):569-75. [Medline].
Waldman SD. Diabetic neuropathy: diagnosis and treatment for the pain management specialist. Curr Rev Pain. 2000. 4(5):383-7. [Medline].
Davidson MB. Diabetes Mellitus: Diagnosis and Treatment. 4th Ed. 1998. 297-307.
Vinik AI. New Methods to Assess Diabetic Neuropathy for Clinical Research.60th Scientific Sessions of the American Diabetes Association. American Diabetes Association; 2000.
Busko M. Common Tests May Miss Pediatric Diabetic Neuropathy. Medscape Medical News. Apr 11 2014. [Full Text].
Hirschfeld G, von Glischinski M, Blankenburg M, et al. Screening for peripheral neuropathies in children with diabetes: a systematic review. Pediatrics. 2014 Apr 7. [Medline].
Tkac I, Bril V. Glycemic control is related to the electrophysiologic severity of diabetic peripheral sensorimotor polyneuropathy. Diabetes Care. 1998 Oct. 21(10):1749-52. [Medline].
Bril V. Electrophysiologic testing. Gries FA, Cameron NE, Low PA, Ziegler D. Textbook of Diabetic Neuropathy. Stuttgart, Germany: Thieme Medical Publishers; 2003. 177-84.
Huang CC, Chen TW, Weng MC, Lee CL, Tseng HC, Huang MH. Effect of glycemic control on electrophysiologic changes of diabetic neuropathy in type 2 diabetic patients. Kaohsiung J Med Sci. 2005 Jan. 21(1):15-21. [Medline].
Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006 Jun. 29(6):1294-9. [Medline].
Apfel SC. Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med. 1999 Aug 30. 107(2B):34S-42S. [Medline].
Apfel SC. Diabetic Polyneuropathy. Diabetes and Endocrinology Clinical Management. 1999.
Argoff CE, Backonja MM, Belgrade MJ, Bennett GJ, Clark MR, Cole BE, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006 Apr. 81(4 Suppl):S12-25. [Medline].
Boulton A. Current and Emerging Treatments for Diabetic Neuropathies. Diabetes Reviews. 7:379-86.
Slovenkai MP. Foot problems in diabetes. Med Clin North Am. 1998 Jul. 82(4):949-71. [Medline].
O'Brien SP, Schwedler M, Kerstein MD. Peripheral neuropathies in diabetes. Surg Clin North Am. 1998 Jun. 78(3):393-408. [Medline].
Skyler JS. Diabetic complications. The importance of glucose control. Endocrinol Metab Clin North Am. 1996 Jun. 25(2):243-54. [Medline].
Martin CL, Albers J, Herman WH, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006 Feb. 29(2):340-4. [Medline].
Sumner CJ, Sheth S, Griffin JW, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003 Jan 14. 60(1):108-11. [Medline].
Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012 Jun 13. 6:CD007543. [Medline].
Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011 Mar 16. CD007938. [Medline].
Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come?. Diabetes Care. 2008 Feb. 31 Suppl 2:S255-61. [Medline].
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev. 2009. (4):CD007115. [Medline].
Chou R, Carson S, Chan BK. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials. J Gen Intern Med. 2009 Feb. 24(2):178-88. [Medline].
Hayee MA, Mohammad QD, Haque A. Diabetic neuropathy and zinc therapy. Bangladesh Med Res Counc Bull. 2005 Aug. 31(2):62-7. [Medline].
Kawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M, et al. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(varepsilon)-carboxymethyl lysine. J Diabetes Complications. 2009 Aug 26. [Medline].
Schemmel KE, Padiyara RS, D'Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications. 2009 Sep 10. [Medline].
Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care. 2006 Jul. 29(7):1538-44. [Medline].
Ando H, Takamura T, Nagai Y, Kaneko S,. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy. J Diabetes Complications. 2006 Nov-Dec. 20(6):367-70. [Medline].
Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005 Jan 27. 352(4):341-50. [Medline].
Daousi C, Benbow SJ, MacFarlane IA. Electrical spinal cord stimulation in the long-term treatment of chronic painful diabetic neuropathy. Diabet Med. 2005 Apr. 22(4):393-8. [Medline].
Ahn AC, Bennani T, Freeman R, Hamdy O, Kaptchuk TJ. Two styles of acupuncture for treating painful diabetic neuropathy--a pilot randomised control trial. Acupunct Med. 2007 Jun. 25(1-2):11-7. [Medline].
Miller RD. Anesthesia. 5th ed. New York: Churchill Livingstone; 2000.
Ferreira MC, Carvalho VF, Kamamoto F, Tuma P Jr, Paggiaro AO. Negative pressure therapy (vacuum) for wound bed preparation among diabetic patients: case series. Sao Paulo Med J. 2009. 127(3):166-70. [Medline].
Crouch J. Charcot's joint and bilateral foot neuropathy. Adv Nurse Pract. 2005 Mar. 13(3):18. [Medline].
Pfeiffer MA, Schumer M. Painful or insensitive lower extremity. Therapy for Diabetes Mellitus. American Diabetes Association; 1998.
Somers DL, Somers MF. Treatment of neuropathic pain in a patient with diabetic neuropathy using transcutaneous electrical nerve stimulation applied to the skin of the lumbar region. Phys Ther. 1999 Aug. 79(8):767-75. [Medline].
[Guideline] Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. Prepublished online April 11, 2011. [Full Text].
Tavakoli M, Kallinikos P, Iqbal A, et al. Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. Diabet Med. 2011 Oct. 28(10):1261-7. [Medline]. [Full Text].
Possidente CJ, Tandan R. A survey of treatment practices in diabetic peripheral neuropathy. Prim Care Diabetes. 2009 Nov. 3(4):253-7. [Medline].
Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998 Dec 2. 280(21):1831-6. [Medline].
Bennett GJ, Dworkin RH, Nicholson B. Anticonvulsant Therapy in the Treatment of Neuropathic Pain. Neurology Treatment Update. 2000.
Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology. 2005 Feb. 48(2):252-63. [Medline].
Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009 Aug. 32(8):1479-84. [Medline]. [Full Text].
Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004 Dec 14. 63(11):2104-10. [Medline].
Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011 Apr 11. [Medline].
Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst Rev. 2011 Jan 19. CD005451. [Medline].
FDA Requires Boxed Warning and Risk Mitigation Strategy for Metoclopramide-Containing Drugs. U.S. Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149533.htm. Accessed: May 16, 2000.
Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005 Apr. 28(4):956-62. [Medline].
Brooks M. Tear film dysfunction a marker of diabetic neuropathy. Medscape Medical News. November 7, 2013. Available at http://www.medscape.com/viewarticle/813976. Accessed: November 12, 2013.
|A-alpha (I)||13-20 micrometers||Limb proprioception||Yes|
|A-beta (II)||6-12 micrometers||Limb proprioception, vibration, pressure||Yes|
|A-delta (III)||1-5 micrometers||Mechanical sharp pain||Yes|
|C (IV)||0.2-1.5 micrometers||Thermal pain, mechanical burning pain||No|